Tenax Therapeutics

Additional data from the phase‑3 LEVEL study on TNX‑103 (oral levosimendan) were presented at the ESC congress and show a positive treatment effect, particularly in patients with lower exercise capacity, with benefit increasing with disease severity. The data also demonstrate a marked reduction in NT‑proBNP levels, reportedly superior to other HFpEF phase‑3 studies, which could support the approval pathway for PH‑HFpEF. Several investment firms recently issued positive ratings with price targets between USD 35 and 40, and Tenax holds about USD 118 million in cash, sufficient through Q2 2028. Pre‑market gains in TENX are attributed solely to these clinical updates. » Altro su de.investing.com

Tenax Therapeutics will present topline results of the phase 3 LEVEL study of TNX‑103 (oral levosimendan) on 29 August 2026 in a late‑breaking session of the ESC in Munich; Prof. Sanjiv Shah will present the data. The study in pulmonary hypertension in heart failure with preserved ejection fraction completed recruitment of more than 230 patients in March 2026; the primary endpoint is the 6‑minute walk distance. A prior re‑assessment found a power of over 90% to detect a difference of 25 meters; Tenax plans a database lock and statistical analysis in the coming weeks. » Altro su de.investing.com

Tenax Therapeutics is about to release pivotal Phase‑3 data for its cardiopulmonary portfolio. The focus is on the drug candidate TNX-103, with which the company is pursuing therapies for unmet medical needs. Experts rate the program as promising and see substantial upside potential if the study results are positive. » Altro su finanzen.net